HCPCS Level II E2103: Non-adjunctive Continuous Glucose Monitor/Receiver
Commercial payers pay $157 on average nationally for this procedure.
HCPCS Level II code E2103 describes a non-adjunctive, non-implanted continuous glucose monitor or receiver used as a replacement for standard home glucose monitoring; service type is durable medical equipment and the typical site of service is home use or outpatient settings where continuous glucose monitoring is managed.
Customize your policy alerts
Sign up for hcpcs E2103 policy alerts
Get alerted when payer policies referencing E2103 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
Commercial reimbursement for HCPCS E2103 centers on a BUCA average of $157.20, with individual payers showing meaningful differences in central tendency and dispersion. Blue Cross Blue Shield (BCBS) and Cigna both sit above BUCA on mean values ($189.10 and $115.70 respectively relative to BUCA’s $157.20 for mean), while Aetna ($95.90) and UnitedHealth Group ($132.00) are lower or similar. The presence of high maxima for BCBS ($971.40) and UnitedHealth Group ($415.60) indicates occasional outlier payments that elevate their upper tails, whereas BUCA represents an average commercial benchmark without min/max detail.
Rate dispersion (P75 minus P25) highlights variability by payer: Blue Cross Blue Shield shows the widest interquartile spread at $172.00 (P75 $252.00 minus P25 $80.00), followed by Cigna at $168.80 (P75 $181.90 minus P25 $15.10). UnitedHealth Group’s spread is $84.70 (P75 $168.70 minus P25 $84.30), and Aetna is the tightest at $37.10 (P75 $157.90 minus P25 $18.00). BUCA’s IQR is $160.20 (P75 $216.70 minus P25 $62.50), placing it between the more and less variable commercial payers.